Healthcare

Hydrix Limited (ASX:HYD) has released its Corporate Governance Statement for the financial year ended 30 June 2026, current as at 26 October 2026 and approved by the Board. The accompanying Appendix 4G was signed by Company Secretary Alyn Tai on 27 October 2026. The …

Lumos Diagnostics Holdings Limited (ASX:LDX) has released its Q1 FY27 results and commercial update for the quarter ended 30 September 2026. The update focuses on the US rollout of its FebriDx test following CLIA waiver, along with financial results and manufacturing progress. All figures …

Resonance Health Ltd (ASX:RHT) has released a capital raising presentation for a $6.0 million institutional placement, along with preliminary results from its extended proof-of-concept (EPoC) liver fibrosis study. The placement is priced at 7.2 cents per share, and Bell Potter Securities is lead manager.

Cynata Therapeutics Limited (ASX:CYP) has released its quarterly activity report and Appendix 4C for the period ended 30 September 2026. The quarter followed the release of results from its Phase 2 aGvHD trial and CYP-004 osteoarthritis trial in June 2026, after which the company …

Opthea's Phase 3 COAST and ShORe trials, reported in March 2025, did not show efficacy for sozinibercept in wet age-related macular degeneration, which led to a trading halt. ASX trading then resumed on 3 June 2026. Shareholders approved the name change at a general …

The 9 October update concerned TOGETHER-PsO, a Phase 3b trial comparing Taltz plus Zepbound with Taltz alone. The study enrolled adults with moderate-to-severe plaque psoriasis and obesity, or overweight accompanied by another weight-related condition.

The global INTerpath-001 study enrolled 1,137 patients with completely resected stage IIB–IV melanoma. Its randomised, double-blind design compared intismeran plus pembrolizumab with pembrolizumab alone in the adjuvant setting, where treatment follows surgery.